Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE).

MLA

Duvignaud, Alexandre, et al. “Inhaled Ciclesonide for Outpatient Treatment of COVID-19 in Adults at Risk of Adverse Outcomes: A Randomised Controlled Trial (COVERAGE).” Clinical Microbiology & Infection, vol. 28, no. 7, July 2022, pp. 1010–16. EBSCOhost, https://doi.org/10.1016/j.cmi.2022.02.031.

APA

Duvignaud, A., Lhomme, E., Onaisi, R., Sitta, R., Gelley, A., Chastang, J., Piroth, L., Binquet, C., Dupouy, J., Makinson, A., Lefèvre, B., Naccache, J.-M., Roussillon, C., Landman, R., Wallet, C., Karcher, S., Journot, V., Nguyen, D., Pistone, T., & Bouchet, S. (2022). Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). Clinical Microbiology & Infection, 28(7), 1010–1016. https://doi.org/10.1016/j.cmi.2022.02.031

Chicago

Duvignaud, Alexandre, Edouard Lhomme, Racha Onaisi, Rémi Sitta, Ambre Gelley, Julie Chastang, Lionel Piroth, et al. 2022. “Inhaled Ciclesonide for Outpatient Treatment of COVID-19 in Adults at Risk of Adverse Outcomes: A Randomised Controlled Trial (COVERAGE).” Clinical Microbiology & Infection 28 (7): 1010–16. doi:10.1016/j.cmi.2022.02.031.